Alehegn Gelaye

Learn More
Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side(More)
PATIENT Male, 53 FINAL DIAGNOSIS: Acute Warfarin toxicity Symptoms: - MEDICATION Warfarin Clinical Procedure: - Specialty: Hematology. OBJECTIVE Unusual clinical course. BACKGROUND Warfarin remains the most common anticoagulant in the management of thromboembolic diseases. However, its extensive drug interaction requires frequent monitoring and dose(More)
PATIENT Female, 57 FINAL DIAGNOSIS: Syryngomyelia • cervical SYMPTOMS Acute respiratory insufficiency Medication: - Clinical Procedure: - Specialty: Pulmonology. OBJECTIVE Rare disease. BACKGROUND Failed planned extubation occurs in a minority of patients with acute respiratory failure requiring invasive mechanical ventilation. In patients presenting(More)
  • 1